MMSI Merit Medical Systems Inc.

Merit Medical Launches the Micro ACE™ Advanced Micro-Access System

Merit Medical Launches the Micro ACE™ Advanced Micro-Access System

Micro ACE combines a unique balance of stiffness and resiliency to achieve successful micro-access in challenging cases

SOUTH JORDAN, Utah, March 19, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced commercial release of its US Food and Drug Administration (FDA)-cleared Micro ACE Advanced Micro-Access System. Merit also intends to file Micro ACE for CE mark designation.

The Micro ACE system is the latest innovation in the Merit Vascular portfolio. The comprehensive portfolio includes a full range of percutaneous access and closure devices. Combining a balance of stiffness and resiliency, Micro ACE is designed to achieve micro-access in a wide range of vascular anatomies.

Interventional procedures utilizing micro-access are commonly performed to diagnose and open narrowed (i.e., atherosclerotic) blood vessels. Atherosclerosis is an inflammatory condition that develops when there is a buildup of plaque inside the arteries. Diseases linked to atherosclerosis, such as coronary and peripheral artery disease, are the leading cause of death in the United States.1

To facilitate such interventional procedures, the Micro ACE balances stiffness and flexibility to offer twice the resistance to kink and compression over the leading competitor. 2 It is also 9% stiffer than the leading standard micro-introducer. 2 In addition, a unique marker tip design allows for nine times greater visibility under fluoroscopy for accurate positioning needed at the start of a procedure.2 Merit is pursuing patents on Micro ACE technology in the United States and internationally.

“Merit has always looked for opportunities to improve patient care. Micro ACE leverages our experience with reinforced sheath design to improve a procedure that is done over and over each day,” said Fred P. Lampropoulos, Merit’s Chairman and CEO. “We are excited to partner with interventional physicians to advance vascular access.”

ABOUT MERIT MEDICAL

Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling in excess of 700 individuals. Merit employs approximately 7,000 people worldwide.

TRADEMARKS

Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc., its subsidiaries, or its licensors.

CONTACTS 

PR/Media Inquiries 

Sarah Comstock 

Merit Medical 

|  

INVESTOR INQUIRIES 

Mike Piccinino, CFA, IRC 

Westwicke - ICR 

| 

1. National Heart, Lung, and Blood Institute (NIH). 2022. “Atherosclerosis.” Last modified March 24, 2022. Accessed March 18, 2024.

2. Data on File.



EN
19/03/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Merit Medical Systems Inc.

 PRESS RELEASE

Merit Medical Appoints F. Ann Millner as Chair of the Board and Announ...

Merit Medical Appoints F. Ann Millner as Chair of the Board and Announces Projected Preliminary Unaudited Revenue Results for the Fourth Quarter of 2025 SOUTH JORDAN, Utah, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced that its Board of Directors unanimously appointed F. Ann Millner, Ed.D., formerly Merit’s Lead Independent Director, as Chair of the Board effective January 5, 2026. Dr. Millner has served as a director of Merit since 2015 and as the Lead Independent Director since July 2021. She prev...

 PRESS RELEASE

Merit Medical to Participate at the J.P. Morgan Healthcare Conference

Merit Medical to Participate at the J.P. Morgan Healthcare Conference SOUTH JORDAN, Utah, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced that management will participate in the 44th Annual J.P. Morgan Healthcare Conference, which is being held at The Westin St. Francis Hotel in San Francisco, California, January 12-15, 2026. To learn more, visit  Martha G. Aronson, President and Chief Executive Officer, and Raul Parra, Chief Financial Officer, will present a company overview and update on Tuesday, Ja...

Merit Medical Systems Inc: 1 director

A director at Merit Medical Systems Inc sold 10,000 shares at 88.038USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...

 PRESS RELEASE

Merit Medical Provides Update on U.S. Reimbursement and Commercial Str...

Merit Medical Provides Update on U.S. Reimbursement and Commercial Strategies for WRAPSODY® Cell-Impermeable Endoprosthesis SOUTH JORDAN, Utah, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that the U.S. Centers for Medicare & Medicaid Services (“CMS”) has notified Merit that its application for Transitional Pass-Through (“TPT”) incremental payment for WRAPSODY® Cell-Impermeable Endoprosthesis (“CIE”) procedures in the outpatient and ambulatory surgery center (“ASC”) settings requires further conside...

 PRESS RELEASE

Merit Medical Releases 24-Month Efficacy Results from the Randomized A...

Merit Medical Releases 24-Month Efficacy Results from the Randomized Arteriovenous Fistula (AVF) Arm of the WRAPSODY Arteriovenous Access Efficacy (WAVE) Trial The target lesion primary patency (TLPP)1 and access circuit primary patency (ACPP)2 of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE) remain superior to percutaneous transluminal angioplasty (PTA) through 24 monthsThe clinical improvements associated with the WRAPSODY CIE are projected to improve the interventional landscape for hemodialysis patients who experience venous outflow obstructions SOUTH JORDAN, Utah, Nov. 05, 2025...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch